Budesonide and the risk of pneumonia: a meta-analysis of individual patient data (Q33498280)

27 July 2017

0 references

Budesonide and the risk of pneumonia: a meta-analysis of individual patient data (English)

1 reference

27 July 2017

0 references

1 reference

Xuekui Zhang

3

0 references

Donald P Tashkin

2

object named as

Donald Tashkin

1 reference

27 July 2017

Don D Sin

1

1 reference

27 July 2017

Finn Radner

4

1 reference

27 July 2017

Ulf Sjöbring

5

1 reference

27 July 2017

Anders Thorén

6

1 reference

27 July 2017

Peter M A Calverley

7

1 reference

27 July 2017

Stephen I Rennard

8

1 reference

27 July 2017

language of work or name

English

0 references

publication date

1 August 2009

1 reference

27 July 2017

1 reference

27 July 2017

volume

374

1 reference

27 July 2017

issue

9691

1 reference

27 July 2017

page(s)

712-719

1 reference

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

27 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961250-2

7 January 2021

Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961250-2

7 January 2021

Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961250-2

7 January 2021

The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961250-2

7 January 2021

Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961250-2

7 January 2021

Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961250-2

7 January 2021

Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961250-2

7 January 2021

Patients Hospitalized After Initial Outpatient Treatment for Community-Acquired Pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961250-2

7 January 2021

Patients admitted to hospital with suspected pneumonia and normal chest radiographs: epidemiology, microbiology, and outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961250-2

7 January 2021

Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961250-2

7 January 2021

Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961250-2

7 January 2021

Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961250-2

7 January 2021

Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961250-2

7 January 2021

Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961250-2

7 January 2021

Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961250-2

7 January 2021

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961250-2

7 January 2021

A 4-year trial of tiotropium in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961250-2

7 January 2021

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961250-2

7 January 2021

Occurrence of community-acquired respiratory tract infection in patients receiving esomeprazole: retrospective analysis of adverse events in 31 clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961250-2

7 January 2021

Binding of glucocorticoids to human nasal tissue in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961250-2

7 January 2021

Plasma concentrations of fluticasone propionate and budesonide following inhalation: effect of induced bronchoconstriction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961250-2

7 January 2021

Microbiologic Determinants of Exacerbation in Chronic Obstructive Pulmonary Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961250-2

7 January 2021

Fluticasone and budesonide inhibit cytokine release in human lung epithelial cells and alveolar macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961250-2

7 January 2021

Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961250-2

7 January 2021

Long-term safety of once-daily budesonide in patients with early-onset mild persistent asthma: results of the Inhaled Steroid Treatment as Regular Therapy in Early Asthma (START) study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961250-2

7 January 2021

Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961250-2

7 January 2021

A prediction rule to identify low-risk patients with community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961250-2

7 January 2021

Withdrawal from treatment as an outcome in the ISOLDE study of COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961250-2

7 January 2021

10.1016/S0140-6736(09)61250-2

Identifiers

DOI

1 reference

27 July 2017

1 reference